Mizuho raised the firm’s price target on Amylyx (AMLX) to $8 from $7 and keeps an Outperform rating on the shares. Following the updated Phase data for AMX0035 in Wolfram syndrome, the firm increased its probability of success to 50% from 30% and now project speak risk-adjusted/risk-unadjusted sales of $174.8M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Positive Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising HELIOS Trial Results for AMX0035
- Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges
- Amylyx announces results from Phase 2 HELIOS trial of AMX0035
- Amylyx price target raised to $16 from $12 at H.C. Wainwright
- Amylyx Pharmaceuticals Advances Clinical Trials and Strengthens Finances